Compare BridgeBio Pharma Inc (BBIO) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs iShares 1 3 Year Treasury Bond ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while iShares 1 3 Year Treasury Bond ETF trades at $81.9. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | SHY | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Fixed Income |
52-Week High | $90.17 | $83.18 |
52-Week Low | $47.29 | $81.77 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
SHY, the iShares 1-3 Year Treasury Bond ETF, trades at $81.92, up 0.15% on the day, with a bearish technical bias as moving averages signal selling pressure. Recent news highlights institutional accumulation amid rising Treasury yields and inflation concerns, while dividend distributions remain steady.
The outlook is cautious due to interest rate uncertainty and geopolitical tensions affecting bond markets. Risks include Fed policy shifts and oil price volatility, but SHY offers stability for income-focused investors seeking short-term Treasury exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
